CORRESP Filing
AYTU BIOPHARMA, INC
Date: June 2, 2025 · CIK: 0001385818 · Accession: 0001437749-25-019196
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287728
Letter
aytu20250602_corresp.htm
AYTU BIOPHARMA, INC.
7900 East Union Avenue, Suite 920 Denver, Colorado 80237 (720) 437-6580
June 2, 2025
VIA EDGAR
United States
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Aytu BioPharma, Inc. — Registration Statement on Form S-1 (File No. 333-287728 )
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-287728) (the “Registration Statement”) of Aytu BioPharma, Inc. (the “Company”). We respectfully request that the Registration Statement be declared effective as of 5:00 p.m., Eastern Time, on June 4, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Dorsey & Whitney LLP, by calling Josh Erekson at (801) 933-4083.
Very truly yours,
AYTU BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm aytu20250602_corresp.htm AYTU BIOPHARMA, INC. 7900 East Union Avenue, Suite 920 Denver, Colorado 80237 (720) 437-6580 June 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aytu BioPharma, Inc. — Registration Statement on Form S-1 (File No. 333-287728 ) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-287728) (the “Registration Statement”) of Aytu BioPharma, Inc. (the “Company”). We respectfully request that the Registration Statement be declared effective as of 5:00 p.m., Eastern Time, on June 4, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Dorsey & Whitney LLP, by calling Josh Erekson at (801) 933-4083. Very truly yours, AYTU BIOPHARMA, INC. /s/ Joshua R. Disbrow Name: Joshua R. Disbrow Title: Chief Executive Officer